Scarica l'app Stockscreener
3.97
2.06%
0.08
Dopo l'orario di chiusura:
4.05
0.08
+2.02%
Precedente Chiudi:
$3.89
Aprire:
$3.88
Volume 24 ore:
47,205
Relative Volume:
1.16
Capitalizzazione di mercato:
$32.86M
Reddito:
-
Utile/perdita netta:
$-30.16M
Rapporto P/E:
-8.6304
EPS:
-0.46
Flusso di cassa netto:
$-39.49M
1 W Prestazione:
+0.25%
1M Prestazione:
+22.93%
6M Prestazione:
+1,176%
1 anno Prestazione:
+922.93%
Intervallo 1D:
$3.76
$4.22
Intervallo di 1 settimana:
$3.76
$4.28
Portata 52W:
$0.27
$4.28
Dare Bioscience Inc Stock (DARE) Company Profile
Nome
Dare Bioscience Inc
Settore
Industria
Telefono
858-926-7655
Indirizzo
3655 NOBEL DRIVE, SAN DIEGO, CA
Dare Bioscience Inc Borsa (DARE) Ultime notizie
Dare BioscienceCatering To Women - RTTNews
Is Bavarian Nordic (BVNRY) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Will It Be A December To Remember For Daré Bioscience? - RTTNews
Daré Bioscience (NASDAQ:DARE) Publishes Corporate Presentation - Defense World
Daré Bioscience Enhances Investor Engagement with New Presentation - TipRanks
Daré Bioscience enters into $15M stock purchase agreement - MSN
Dare Bioscience shares retain Buy rating on funding reward By Investing.com - Investing.com Canada
Dare Bioscience awarded $10M for HPV treatment development - Investing.com India
Dare Bioscience awarded $10M for HPV treatment development By Investing.com - Investing.com South Africa
Daré Bioscience Selected to Receive $10 Million Award from ARPA-H’s Sprint for Women’s Health - The Bakersfield Californian
Daré Bioscience Enters Purchase Agreement with Lincoln Park Capital Fund - Defense World
Dare Bioscience secures $15 million funding agreement By Investing.com - Investing.com Australia
Dare Bioscience secures $15 million funding agreement - Investing.com
Daré Bioscience Announces Common Stock Purchase Agreement - GlobeNewswire
Daré Bioscience Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC - StockTitan
Brookline Capital Downgrades Daré Bioscience (DARE) - MSN
Bill Gates helped fund birth control microchip but didn't invent it | Fact check - USA TODAY
Dye & Durham Limited - Baystreet.ca
DADA’s 2023 Market Dance: Down -64.46% – Time to Invest? - The InvestChronicle
Barrow Hanley Mewhinney & Strauss LLC Raises Stake in Darling Ingredients Inc. (NYSE:DAR) - Defense World
Darling Ingredients Inc. (NYSE:DAR) Shares Sold by Meiji Yasuda Asset Management Co Ltd. - Defense World
MDA Space shares target raised on Telesat Lightspeed deals By Investing.com - Investing.com Australia
The Dare Announce 2024 Australian Headlining Shows - Music Feeds
The Dare Shares Inaugural Australian Tour Dates - The Music
ADMA Biologics stock soars to all-time high of $19.36 - Investing.com
The massive, untapped opportunity in women’s health - BioWorld Online
Daré Bioscience (NASDAQ:DARE) Share Price Crosses Below Two Hundred Day Moving Average of $4.51 - Defense World
Daré Bioscience (NASDAQ:DARE) Stock Price Passes Below Two Hundred Day Moving Average of $4.59 - Defense World
Its Stock Has Paid Off Big Time For Dare Bioscience Inc - SETE News
Daré Bioscience Announces Publication in The Journal of - GlobeNewswire
Sildenafil cream shows promise for FSAD without common side effects - Investing.com
Daré Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Safety Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6% - StockTitan
Daré Bioscience (NASDAQ:DARE) Shares Pass Below Two Hundred Day Moving Average of $4.62 - Defense World
Daré Bioscience, Inc. (NASDAQ:DARE) to Post FY2024 Earnings of ($0.33) Per Share, Brookline Capital Management Forecasts - Defense World
HC Wainwright Comments on Daré Bioscience, Inc.’s Q3 2024 Earnings (NASDAQ:DARE) - Defense World
Maxim Group Reiterates “Hold” Rating for Daré Bioscience (NASDAQ:DARE) - Defense World
Sildenafil Cream study suggests simplified patient reporting - Investing.com
Sildenafil Cream study suggests simplified patient reporting By Investing.com - Investing.com Canada
Dare Bioscience Inc (DARE) Q2 2024 Earnings Call Transcript High - GuruFocus.com
Daré Bioscience, Inc. (NASDAQ:DARE) Q2 2024 Earnings Call Transcript - Insider Monkey
Daré Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6% - StockTitan
Earnings call: Daré Bioscience reports progress in women's health treatments - Investing.com
DARE Stock Earnings: Dare Bioscience Beats Revenue for Q2 2024 - InvestorPlace
Daré Bioscience, Inc. (DARE) Q2 2024 Earnings Call Transcript - Seeking Alpha
Dare Bioscience, Inc. (DARE) Q2 Earnings Top Estimates - MSN
Daré Bioscience Reports Second Quarter 2024 Financial Results and Provides Company Update - GlobeNewswire
Financial Contrast: Daré Bioscience (NASDAQ:DARE) vs. Newron Pharmaceuticals (OTCMKTS:NWPHF) - Defense World
Daré Bioscience (DARE) Set to Announce Earnings on Monday - Defense World
Daré Bioscience to Host Second Quarter 2024 Financial - GlobeNewswire
Daré Bioscience to Host Second Quarter 2024 Financial Results and Company Update Conference Call and Webcast on August 12, 2024 - StockTitan
Daré Bioscience (NASDAQ:DARE) Shares Cross Below 200-Day Moving Average of $4.67 - Defense World
Dare Bioscience Inc Azioni (DARE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.02%
0.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):